Nanyang Biologics Poised for Public Debut: A $1.5B SPAC Deal Signals a New Era in AI-Driven Drug Discovery

Nanyang Biologics Poised for Public Debut: A $1.5B SPAC Deal Signals a New Era in AI-Driven Drug Discovery

In a move that underscores the accelerating convergence of artificial intelligence and biotechnology, Nanyang Biologics Pte. Ltd. (NYB) has announced a significant business combination agreement with RF Acquisition Corp II (RFAI). This transaction, valued at approximately $1.5 billion, is set to propel NYB towards a public listing on the Nasdaq stock exchange, signaling a new chapter for the AI-driven drug discovery pioneer. The deal is anticipated to close in the first or second quarter of 2026, pending shareholder approvals and customary closing conditions.

Revolutionizing Drug Discovery with AI and Natural Compounds

Nanyang Biologics has carved a niche for itself by developing a comprehensive drug discovery platform that uniquely integrates the wisdom of traditional medicine with cutting-edge technological advancements. At the heart of its operations lies the proprietary Vecura™ AI platform, powered by the innovative Drug-Target Interaction Graph Neural Network (DTIGN). This sophisticated AI model is designed to rapidly identify promising drug candidates by translating vast biochemical spaces into feasible therapeutic options, thereby significantly reducing research and development costs and timelines. In 2024, the DTIGN engine demonstrated its prowess by outperforming competitors by 27% in benchmarking tests, a feat recognized and published in the prestigious IEEE magazine. Further validating its innovative edge, the DTIGN engine also secured the 1st Prize at the SuperAI Genesis Startup Competition 2025, competing against over 700 global startups.

The company’s strategy is further bolstered by its commitment to building one of the world's largest AI-curated natural compound libraries, anchored in Singapore. This ambitious project is undertaken in strategic collaboration with global technology leaders, including NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix, alongside top-tier research institutions. This integrated ecosystem aims to redefine AI-driven drug discovery, paving the way for next-generation pharmaceuticals, functional foods, and personalized healthcare solutions.

A Promising Pipeline Anchored by NB-A002

Leveraging its advanced AI capabilities, NYB has already identified several nature-inspired small molecules that are progressing through preclinical stages. These include NB-B101 for solid tumors, NB-C201 for cardiovascular health, and NB-C301 for mental health. The company’s pipeline is supported by a robust intellectual property portfolio, encompassing international patent applications and early-stage provisional patents, targeting high-unmet needs across oncology, cardiovascular diseases, and mental health therapeutics.

A standout candidate in NYB's pipeline is NB-A002, a first-in-class oncology therapy designed to target the previously undruggable ILF2 protein. This innovative approach induces synthetic lethality in cancers with DNA Damage Response (DDR) and Homologous Recombination Deficiency (HRD), offering a potential superior alternative to existing PARP inhibitors. NB-A002 holds promise for treating a range of solid tumors, including ovarian, breast, and lung cancers, particularly those with BRCA mutations or BRCAness characteristics. The market potential for DDR therapies is substantial, valued at $8.3 billion currently and projected to reach $19.5 billion by the mid-2030s. Given that 91% of pan-cancer cases in Chinese populations exhibit actionable DDR/HRD alterations, NB-A002 is strategically positioned to address a significant unmet demand in oncology, especially within Asian markets.

Pioneering Collaboration with Nanyang Technological University

NYB’s scientific endeavors are significantly amplified by its pioneering joint laboratory collaboration with Nanyang Technological University Singapore (NTU). NTU, recognized globally as an AI powerhouse and ranked second worldwide for AI by U.S. News & World Report 2025, provides a fertile ground for innovation. The NYB-NTU joint laboratory is focused on developing the next generation of AI engines that underpin the Vecura™ AI platform. This partnership harnesses the combined power of advanced AI and the therapeutic potential inherent in natural compounds to accelerate discovery across various modalities, including small molecules and biologics, further supporting NYB’s vision of extending human longevity.

Management